000250 — Sam Chun Dang Pharm Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeLarge CapHigh Flyer

Annual income statement for Sam Chun Dang Pharm Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	166,862	167,275	177,335	192,669	210,924
Cost of Revenue
Gross Profit	94,000	83,078	89,995	96,966	99,662
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	161,843	183,057	165,111	184,154	208,344
Operating Profit	5,019	-15,782	12,225	8,514	2,580
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	16,581	-19,549	8,920	-4,549	11,038
Provision for Income Taxes
Net Income After Taxes	7,495	-10,361	8,832	-4,188	-5,078
Minority Interest
Net Income Before Extraordinary Items
Net Income	-966	-16,555	5,838	-10,383	-10,916
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-966	-16,555	5,838	-10,383	-10,916
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-33.7	-737	229	-441	-470
Dividends per Share